Even after the knock, Novo Nordisk's rating is fat

11 February 2013 | By Quentin Webb

The Danish drugmaker lost about $14 bln in market value after U.S. regulators held off approving a new insulin treatment. As the world grows obese, the diabetes specialist should profit handsomely. But the shares look rich, even after the 13 pct markdown.

Please login